Predictors of antibody persistence to the 7-valent pneumococcal conjugate vaccine in healthy Fijian infants at 12 months of age

被引：1
|
作者：
Lindholm, Daniel E. [1 ,2 ]
Licciardi, Paul, V [1 ,2 ]
Ratu, Felisita T. [1 ]
Mulholland, E. Kim [1 ,3 ]
Nguyen, Cattram D. [1 ,4 ]
Russell, Fiona M. [1 ,2 ]
机构：
[1] Murdoch Childrens Res Inst MCRI, Infect & Immun, Melbourne, Vic, Australia
[2] Univ Melbourne, Ctr Int Child Hlth, Dept Paediat, Melbourne, Vic, Australia
[3] London Sch Hyg & Trop Med, London, England
[4] Murdoch Childrens Res Inst, Clin Epidemiol & Biostat Unit, Melbourne, Vic, Australia
来源：
VACCINE | 2020年 / 38卷 / 33期
关键词：
Pneumococcal conjugate vaccine; Poor antibody persistence; Ethnicity; Reduced-dose schedule; Fiji; Infant; NASOPHARYNGEAL CARRIAGE; POLYSACCHARIDE VACCINE; IMMUNE-RESPONSES; CHILDREN; IMPACT;
D O I：
10.1016/j.vaccine.2020.06.025
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Little is known about the predictors of antibody persistence to pneumococcal conjugate vaccines (PCV) in the context of reduced dose schedules. In Fiji, an RCT investigated 0, 1, 2 and 3 dose schedules of 7-valent PCV administered at 6, 10 and 14 weeks of age in 364 healthy infants. This study was a post-hoc analysis of the predictors of poor antibody persistence at 12 months, prior to a booster, using univariable and multivariable analyses. The strongest predictors of poor antibody persistence as measured by serotype-specific immunoglobulin G (IgG) and opsonophagocytosis (OI) assays were being of Indigenous Fijian ethnicity (IgG: adjusted odds ratio (aOR) 3.43, p < 0.001; OI: aOR 1.96, p = 0.013) and receipt of fewer than 3 doses of PCV. These findings may help to identify which children may be at an increased risk of pneumococcal disease in the context of reduced dose primary series PCV schedules. (C) 2020 Elsevier Ltd. All rights reserved.
引用
收藏
页码：5095 / 5099
页数：5
相关论文
共 50 条
  • [41] Safety and immunogenicity of a new 13-valent pneumococcal conjugate vaccine versus a licensed 7-valent pneumococcal conjugate vaccine: a study protocol of a randomised non-inferiority trial in China
    Chen, Jing Jing
    Yuan, Lin
    Huang, Zhen
    Shi, Nian Min
    Zhao, Yu Liang
    Xia, Sheng Li
    Li, Guo Hua
    Li, Rong Cheng
    Li, Yan Ping
    Yang, Shu Yuan
    Xia, Jie Lai
    BMJ OPEN, 2016, 6 (10):
  • [42] Relationship between Serotypes, Age, and Clinical Presentation of Invasive Pneumococcal Disease in Madrid, Spain, after Introduction of the 7-Valent Pneumococcal Conjugate Vaccine into the Vaccination Calendar
    Picazo, J.
    Ruiz-Contreras, J.
    Casado-Flores, J.
    Giangaspro, E.
    Del Castillo, F.
    Hernandez-Sampelayo, T.
    Otheo, E.
    Balboa, F.
    Rios, E.
    Mendez, C.
    CLINICAL AND VACCINE IMMUNOLOGY, 2011, 18 (01) : 89 - 94
  • [43] The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients
    Nagel, Johanna
    Geborek, Pierre
    Saxne, Tore
    Jonsson, Goran
    Englund, Martin
    Petersson, Ingemar F.
    Nilsson, Jan-Ake
    Truedsson, Lennart
    Kapetanovic, Meliha C.
    ARTHRITIS RESEARCH & THERAPY, 2015, 17
  • [44] Socioeconomic and Racial Disparities of Pediatric Invasive Pneumococcal Disease After the Introduction of the 7-valent Pneumococcal Conjugate Vaccine
    Spicer, Jennifer O.
    Thomas, Stephanie
    Holst, Amy
    Baughman, Wendy
    Farley, Monica M.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (02) : 158 - 164
  • [45] Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany
    Rueckinger, Simon
    van der Linden, Mark
    Reinert, Ralf Rene
    von Kries, Ruediger
    Burckhardt, Florian
    Siedler, Anette
    VACCINE, 2009, 27 (31) : 4136 - 4141
  • [46] Salivary Immune Responses to the 7-Valent Pneumococcal Conjugate Vaccine in the First 2 Years of Life
    Rodenburg, Gerwin D.
    Sanders, Elisabeth A. M.
    van Gils, Elske J. M.
    Veenhoven, Reinier H.
    Zborowski, Tomasz
    van den Dobbelsteen, Germie P. J. M.
    Bloem, Andries C.
    Berbers, Guy A. M.
    Bogaert, Debby
    PLOS ONE, 2012, 7 (10):
  • [47] Immunization with the 7-valent conjugate pneumococcal vaccine: Impact evaluation, continuing surveillance and future perspectives
    Bechini, Angela
    Boccalini, Sara
    Bonanni, Paolo
    VACCINE, 2009, 27 (25-26) : 3285 - 3290
  • [48] Pediatric hospitalization for pneurnococcal diseases preventable by 7-valent pneumococcal conjugate vaccine in Hong Kong
    Ho, Pak-Leung
    Chiu, Susan S.
    Chow, Frankie K. H.
    Mak, Gannon C.
    Lau, Yu Lung
    VACCINE, 2007, 25 (39-40) : 6837 - 6841
  • [49] Streptococcus pneumoniae meningitis in Alberta pre- and postintroduction of the 7-valent pneumococcal conjugate vaccine
    Johnstone, Jennie
    Tyrrell, Gregory J.
    Marrie, Thomas J.
    Garg, Sipi
    Kellner, James D.
    CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2011, 22 (04) : 137 - 141
  • [50] Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial
    Simon, Michael W.
    Bataille, Regine
    Caldwell, Nicole S.
    Gessner, Bradford D.
    Jodar, Luis
    Lamberth, Erik
    Peng, Yahong
    Scott, Daniel A.
    Lei, Lanyu
    Giardina, Peter C.
    Gruber, William C.
    Jansen, Kathrin U.
    Thompson, Allison
    Watson, Wendy
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (02)
12345